1. Basic Information
Disease Protected Against
Streptococcus pneumoniae (Pneumococcus) is a bacterium causing invasive pneumococcal disease (IPD) including bacteremia and meningitis; pneumonia; and otitis media. Before vaccination, pneumococcus was the leading cause of bacterial meningitis and bacteremia in young children. There are >100 serotypes; PCV vaccines target the most clinically significant ones. IPD has a case-fatality rate of ~5–15% in children and can cause permanent neurological sequelae in meningitis survivors.
CDC Schedule (U.S., 2025)
| Dose | Age | Product |
|---|---|---|
| Dose 1 | 2 months | PCV13 or PCV15 or PCV20 |
| Dose 2 | 4 months | PCV13 or PCV15 or PCV20 |
| Dose 3 | 6 months | PCV13 or PCV15 or PCV20 |
| Dose 4 (booster) | 12–15 months | PCV13 or PCV15 or PCV20 |
Source: CDC ACIP, 2025 schedule. PCV7 (7-valent) was introduced in 2000, replaced by PCV13 in 2010. PCV15 and PCV20 were licensed in 2021–2023. The schedule is transitioning to higher-valency products.
2. Pre-Licensure Clinical Trial Data
PCV7 (Prevnar, 2000) was licensed based on a pivotal efficacy trial in ~38,000 infants — one of the largest pediatric vaccine pre-licensure programs. PCV13 (2010) was licensed based on immunogenicity non-inferiority trials comparing to PCV7 plus safety data from ~6,000 infants. PCV15 and PCV20 were licensed based on immunogenicity bridging studies.
| Metric | PCV7 Data | PCV13 Data |
|---|---|---|
| Pivotal trial size | ~38,000 infants (NCKP trial) | ~6,000 infants (safety); immunogenicity in ~3,200 |
| Efficacy (IPD, vaccine types) | ~97% | Immunobridged; real-world data confirm high effectiveness |
| Most common reactions | Injection site pain (10–20%), fever >38°C (15–25%), irritability (20–40%), decreased appetite (10–20%), drowsiness (15–30%) | Similar to PCV7; slightly higher rate of local reactions compared to PCV7 due to additional serotypes |
The PCV7 pivotal trial was notable for its size and for using a saline placebo, providing one of the most robust pre-licensure safety databases for any pediatric vaccine. PCV13 and subsequent products used active comparators (PCV7) rather than placebo.
Key Limitations
- Serotype replacement: PCV vaccines reduce disease caused by vaccine serotypes, but non-vaccine serotypes can increase in prevalence (serotype replacement). This has been observed post-PCV7 and post-PCV13, necessitating development of higher-valency vaccines.
- Febrile seizure risk with concomitant influenza vaccine: PCV13 given concomitantly with trivalent inactivated influenza vaccine (TIV) was associated with a small increased risk of febrile seizures in the 2010–2011 season (~1 additional seizure per 2,000–2,500 doses). This was not observed with PCV13 alone or with other concomitant vaccine combinations.
3. Post-Licensure Safety Data
PCV vaccines have extensive post-licensure safety data from VSD and VAERS, spanning >25 years for PCV7/PCV13. Key VSD findings:
- Febrile seizures: PCV13 + TIV combination identified as a safety signal in VSD rapid cycle analysis (2010–2011). Signal resolved. PCV13 alone is not associated with increased febrile seizure risk.
- No other consistent safety signals have been identified in VSD for PCV vaccines independently. IOM (2012) did not identify specific safety concerns for PCV.
⚠ Critical Caveat
VAERS data represent unverified reports. A report to VAERS does not mean the vaccine caused the event.
4. Documented Adverse Events
▶ Strong Evidence
- Injection site reactions: Pain (~10–20%), swelling (~5–15%). Strong
- Fever: 15–25% (>38°C); 1–5% (>39°C). Strong
- Irritability/decreased appetite/drowsiness: 15–40% in infants. Self-limited. Strong
- Febrile seizures (PCV13 + TIV combination): Small increased risk when co-administered; ~1 per 2,000–2,500 doses. Strong
- Anaphylaxis: ~1 per million doses. Strong
▶ No Causal Association
- SIDS: No association. No Association
- Autism: No association. No Association
5. Disease Prevention Benefits
| Metric | Pre-Vaccine Era | Post-PCV Era |
|---|---|---|
| IPD in children <5 (annual, U.S.) | ~16,000–17,000 cases (~190 per 100,000) | >90% reduction; vaccine-type IPD near-elimination in children |
| Pneumococcal meningitis (children <2) | ~1,300 cases/year | <50 cases/year (vaccine types) |
| All-cause pneumonia hospitalizations (children <2) | Baseline pre-PCV7 | ~35–40% reduction; substantial herd protection in unvaccinated and older adults |
| Otitis media | Very high; most common reason for pediatric antibiotic prescriptions | ~20–25% reduction in all-cause otitis media visits; larger reduction in vaccine-type OM |
Source: CDC Pink Book; MMWR. PCV has produced substantial herd protection, reducing IPD in unvaccinated adults and the elderly.
6. Evidence Summary
PCV vaccines have a robust evidence base. The PCV7 pivotal trial (N=38,000) was among the largest pediatric vaccine pre-licensure studies ever conducted, with a true saline placebo. Post-licensure VSD data span >25 years. The primary evidence gaps relate to serotype replacement dynamics (ongoing), the safety of newer higher-valency products relative to established products (post-licensure data still limited for PCV15/PCV20), and the long-term population-level impact of PCV on non-vaccine serotypes.
7. Key References
- Black S, Shinefield H, Fireman B, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr Infect Dis J. 2000;19(3):187–195. (NCKP trial)
- IOM. Adverse Effects of Vaccines: Evidence and Causality. National Academies Press; 2012.
- CDC. Pink Book — Pneumococcal chapter. cdc.gov/pinkbook
- Tse A, et al. Signal identification and evaluation for febrile seizures after PCV13 and TIV. Vaccine. 2012.
- CDC. VSD. cdc.gov/vaccine-safety/about/vsd.html
- CDC/FDA. VAERS. vaers.hhs.gov